|
1
|
Ishida Y, Agata Y, Shibahara K and Honjo
T: Induced expression of PD-1, a novel member of the immunoglobulin
gene superfamily, upon programmed cell death. EMBO J. 11:3887–3895.
1992.PubMed/NCBI
|
|
2
|
Dong H, Zhu G, Tamada K and Chen L: B7-H1,
a third member of the B7 family, co-stimulates T-cell proliferation
and interleukin-10 secretion. Nat Med. 5:1365–1369. 1999.PubMed/NCBI View
Article : Google Scholar
|
|
3
|
Chen J, Jiang CC, Jin L and Zhang XD:
Regulation of PD-L1: A novel role of pro-survival signalling in
cancer. Ann Oncol. 27:409–416. 2016.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Boussiotis VA, Chatterjee P and Li L:
Biochemical signaling of PD-1 on T cells and its functional
implications. Cancer J. 20:265–271. 2014.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Wherry EJ: T cell exhaustion. Nat Immunol.
12:492–499. 2011.PubMed/NCBI View
Article : Google Scholar
|
|
6
|
Butte MJ, Keir ME, Phamduy TB, Sharpe AH
and Freeman GJ: Programmed death-1 ligand 1 interacts specifically
with the B7-1 costimulatory molecule to inhibit T cell responses.
Immunity. 27:111–122. 2007.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Latchman YE, Liang SC, Wu Y, Chernova T,
Sobel RA, Klemm M, Kuchroo VK, Freeman GJ and Sharpe AH:
PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting
cells, and host tissues negatively regulates T cells. Proc Natl
Acad Sci USA. 101:10691–10696. 2004.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Brahmer JR, Rizvi NA, Lutzky J, Khleif S,
Blake-Haskins A, Robbins XLB, Vasselli J, Ibrahim RA and Antonia
SJ: Clinical activity and biomarkers of MEDI4736, an anti-PD-L1
antibody, in patients with NSCLC. J Clin Oncol. 32 (15
Suppl)(S8021)2014.
|
|
9
|
Weber J, Mandala M, Del Vecchio M, Gogas
HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V,
Marquez-Rodas I, et al: Adjuvant nivolumab versus ipilimumab in
resected stage III or IV melanoma. N Engl J Med. 377:1824–1835.
2017.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ansell SM, Lesokhin AM, Borrello I,
Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry
D, Freeman GJ, et al: PD-1 blockade with nivolumab in relapsed or
refractory Hodgkin's lymphoma. N Engl J Med. 372:311–319.
2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Antonia SJ, Villegas A, Daniel D, Vicente
D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, et
al: Durvalumab after chemoradiotherapy in stage III non-small-cell
lung cancer. N Engl J Med. 377:1919–1929. 2017.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Motzer RJ, Escudier B, McDermott DF,
George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G,
Plimack ER, et al: Nivolumab versus everolimus in advanced
renal-cell carcinoma. N Engl J Med. 373:1803–1813. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Overman MJ, McDermott R, Leach JL, Lonardi
S, Lenz HJ, Morse MA, Desai J, Hill A, Axelson M, Moss RA, et al:
Nivolumab in patients with metastatic DNA mismatch repair-deficient
or microsatellite instability-high colorectal cancer (CheckMate
142): An open-label, multicentre, phase 2 study. Lancet Oncol.
18:1182–1191. 2017.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y,
Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK,
et al: Pembrolizumab as second-line therapy for advanced urothelial
carcinoma. N Engl J Med. 376:1015–1026. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Kaufman HL, Russell J, Hamid O, Bhatia S,
Terheyden P, D'Angelo SP, Shih KC, Lebbé C, Linette GP, Milella M,
et al: Avelumab in patients with chemotherapy-refractory metastatic
Merkel cell carcinoma: A multicentre, single-group, open-label,
phase 2 trial. Lancet Oncol. 17:1374–1385. 2016.PubMed/NCBI View Article : Google Scholar
|
|
16
|
El-Khoueiry AB, Sangro B, Yau T, Crocenzi
TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, et al:
Nivolumab in patients with advanced hepatocellular carcinoma
(CheckMate 040): An open-label, non-comparative, phase 1/2 dose
escalation and expansion trial. Lancet. 389:2492–2502.
2017.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Fuchs CS, Doi T, Jang RW, Muro K, Satoh T,
Machado M, Sun W, Jalal SI, Shah MA, Metges JP, et al: Safety and
efficacy of pembrolizumab monotherapy in patients with previously
treated advanced gastric and gastroesophageal junction cancer:
Phase 2 clinical KEYNOTE-059 trial. JAMA Oncol.
4(e180013)2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Ferris RL, Blumenschein G Jr, Fayette J,
Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE,
Even C, et al: Nivolumab for recurrent squamous-cell carcinoma of
the head and neck. N Engl J Med. 375:1856–1867. 2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Sunshine J and Taube JM: PD-1/PD-L1
inhibitors. Curr Opin Pharmacol. 23:32–38. 2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Diem S, Hasan Ali O, Ackermann CJ, Bomze
D, Koelzer VH, Jochum W, Speiser DE, Mertz KD and Flatz L: Tumor
infiltrating lymphocytes in lymph node metastases of stage III
melanoma correspond to response and survival in nine patients
treated with ipilimumab at the time of stage IV disease. Cancer
Immunol Immunother. 67:39–45. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Kansy BA, Concha-Benavente F, Srivastava
RM, Jie HB, Shayan G, Lei Y, Moskovitz J, Moy J, Li J, Brandau S,
et al: PD-1 Status in CD8+ T cells associates with
survival and anti-PD-1 therapeutic outcomes in head and neck
cancer. Cancer Res. 77:6353–6364. 2017.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Hellmann MD, Callahan MK, Awad MM, Calvo
E, Ascierto PA, Atmaca A, Rizvi NA, Hirsch FR, Selvaggi G,
Szustakowski JD, et al: Tumor mutational burden and efficacy of
nivolumab monotherapy and in combination with ipilimumab in
small-cell lung cancer. Cancer Cell. 33:853–861.e4. 2018.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Meng X, Huang Z, Teng F, Xing L and Yu J:
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade
immunotherapy. Cancer Treat Rev. 41:868–876. 2015.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Gandini S, Massi D and Mandalà M: PD-L1
expression in cancer patients receiving anti PD-1/PD-L1 antibodies:
A systematic review and meta-analysis. Crit Rev Oncol Hematol.
100:88–98. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Wallis CJD, Lawson K, Butaney M,
Satkunasivam R, Parikh J, Freedland SJ, Patel SP, Hamid O, Pal SK
and Klaassen Z: Association between PD-L1 status and immune
checkpoint inhibitor response in advanced malignancies: A
systematic review and meta-analysis of overall survival data. Jpn J
Clin Oncol. 50:800–809. 2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Davis AA and Patel VG: The role of PD-L1
expression as a predictive biomarker: An analysis of all US Food
and Drug Administration (FDA) approvals of immune checkpoint
inhibitors. J Immunother Cancer. 7(278)2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Wu P, Wu D, Li L, Chai Y and Huang J:
PD-L1 and survival in solid tumors: A meta-analysis. PLoS One.
10(e0131403)2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Pyo JS, Kang G and Kim JY: Prognostic role
of PD-L1 in malignant solid tumors: A meta-analysis. Int J Biol
Markers. 32:e68–e74. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Chen L and Han X: Anti-PD-1/PD-L1 therapy
of human cancer: Past, present, and future. J Clin Invest.
125:3384–3391. 2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Topalian SL, Drake CG and Pardoll DM:
Immune checkpoint blockade: A common denominator approach to cancer
therapy. Cancer Cell. 27:450–461. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Behrends C, Sowa ME, Gygi SP and Harper
JW: Network organization of the human autophagy system. Nature.
466:68–76. 2010.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Sosman JA, Kim KB, Schuchter L, Gonzalez
R, Pavlick AC, Weber JS, McArthur GA, Hutson TE, Moschos SJ,
Flaherty KT, et al: Survival in BRAF V600-mutant advanced melanoma
treated with vemurafenib. N Engl J Med. 366:707–714.
2012.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kaushik S and Cuervo AM: The coming of age
of chaperone-mediated autophagy. Nat Rev Mol Cell Biol. 19:365–381.
2018.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Dash S, Aydin Y and Moroz K:
Chaperone-mediated autophagy in the liver: Good or bad? Cells.
8(1308)2019.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Feng Y, He D, Yao Z and Klionsky DJ: The
machinery of macroautophagy. Cell Res. 24:24–41. 2014.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Glick D, Barth S and Macleod KF:
Autophagy: Cellular and molecular mechanisms. J Pathol. 221:3–12.
2010.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Shibutani ST and Yoshimori T: A current
perspective of autophagosome biogenesis. Cell Res. 24:58–68.
2014.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Hailey DW, Rambold AS, Satpute-Krishnan P,
Mitra K, Sougrat R, Kim PK and Lippincott-Schwartz J: Mitochondria
supply membranes for autophagosome biogenesis during starvation.
Cell. 141:656–667. 2010.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Huang J, Sun R, Qi X, Liu L, Yang Y and
Sun B: Effect of autophagy on expression of neutrophil programmed
death ligand-1 in mice with sepsis. Zhonghua Wei Zhong Bing Ji Jiu
Yi Xue. 31:1091–1096. 2019.PubMed/NCBI View Article : Google Scholar : (In Chinese).
|
|
40
|
Booth L, Roberts JL, Poklepovic A and Dent
P: (Pemetrexed + sildenafil), via autophagy-dependent HDAC
downregulation, enhances the immunotherapy response of NSCLC cells.
Cancer Biol Ther. 18:705–714. 2017.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Dent P, Booth L, Roberts JL, Poklepovic A
and Hancock JF: (Curcumin + sildenafil) enhances the efficacy of
5FU and anti-PD1 therapies in vivo. J Cell Physiol. 235:6862–6874.
2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Chen MC, Lin YC, Liao YH, Liou JP and Chen
CH: MPT0G612, a Novel HDAC6 inhibitor, induces apoptosis and
suppresses IFN-γ-induced programmed death-ligand 1 in human
colorectal carcinoma cells. Cancers (Basel).
11(1617)2019.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Booth L, Roberts JL, West C, Von Hoff D
and Dent P: GZ17-6.02 initiates DNA damage causing
autophagosome-dependent HDAC degradation resulting in enhanced
anti-PD1 checkpoint inhibitory antibody efficacy. J Cell Physiol.
235:8098–8113. 2020.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Booth L, Roberts JL, Poklepovic A,
Avogadri-Connors F, Cutler RE, Lalani AS and Dent P: HDAC
inhibitors enhance neratinib activity and when combined enhance the
actions of an anti-PD-1 immunomodulatory antibody in vivo.
Oncotarget. 8:90262–90277. 2017.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Wang X, Wu WKK, Gao J, Li Z, Dong B, Lin
X, Li Y, Li Y, Gong J, Qi C, et al: Autophagy inhibition enhances
PD-L1 expression in gastric cancer. J Exp Clin Cancer Res.
38(140)2019.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Buchser WJ, Laskow TC, Pavlik PJ, Lin HM
and Lotze MT: Cell-mediated autophagy promotes cancer cell
survival. Cancer Res. 72:2970–2979. 2012.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Tang D, Zhao D, Wu Y, Yao R, Zhou L, Lu L,
Gao W and Sun Y: The miR-3127-5p/p-STAT3 axis up-regulates PD-L1
inducing chemoresistance in non-small-cell lung cancer. J Cell Mol
Med. 22:3847–3856. 2018.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Zhu J, Li Y, Luo Y, Xu J, Liufu H, Tian Z
and Huang C, Li J and Huang C: A feedback loop formed by
ATG7/autophagy, FOXO3a/miR-145 and PD-L1 regulates stem-like
properties and invasion in human bladder cancer. Cancers (Basel).
11(349)2019.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Maher CM, Thomas JD, Haas DA, Longen CG,
Oyer HM, Tong JY and Kim FJ: Small-molecule sigma1 modulator
induces autophagic degradation of PD-L1. Mol Cancer Res.
16:243–255. 2018.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Liang J, Wang L, Wang C, Shen J, Su B,
Marisetty AL, Fang D, Kassab C, Jeong KJ, Zhao W, et al:
Verteporfin Inhibits PD-L1 through autophagy and the
STAT1-IRF1-TRIM28 signaling axis, exerting antitumor efficacy.
Cancer Immunol Res. 8:952–965. 2020.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Zhang N and Bevan MJ: CD8(+) T cells: Foot
soldiers of the immune system. Immunity. 35:161–168.
2011.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Patel SP, Osada T, Osada K, Hurwitz H,
Lyerly HK and Morse MA: Modulation of immune system inhibitory
checkpoints in colorectal cancer. Curr Colorectal Cancer Rep.
9:391–397. 2013.
|
|
53
|
Dunn GP, Old LJ and Schreiber RD: The
three Es of cancer immunoediting. Annu Rev Immunol. 22:329–360.
2004.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Cancer Genome Atlas Research Network.
Comprehensive molecular characterization of gastric adenocarcinoma.
Nature. 513:202–209. 2014.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Green MR, Monti S, Rodig SJ, Juszczynski
P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub
TR, et al: Integrative analysis reveals selective 9p24.1
amplification, increased PD-1 ligand expression, and further
induction via JAK2 in nodular sclerosing Hodgkin lymphoma and
primary mediastinal large B-cell lymphoma. Blood. 116:3268–3277.
2010.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Ikeda S, Okamoto T, Okano S, Umemoto Y,
Tagawa T, Morodomi Y, Kohno M, Shimamatsu S, Kitahara H, Suzuki Y,
et al: PD-L1 is upregulated by simultaneous amplification of the
PD-L1 and JAK2 genes in non-small cell lung cancer. J Thorac Oncol.
11:62–71. 2016.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Roemer MG, Advani RH, Ligon AH, Natkunam
Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GJ, et
al: PD-L1 and PD-L2 genetic alterations define classical Hodgkin
lymphoma and predict outcome. J Clin Oncol. 34:2690–2697.
2016.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Twa DD, Chan FC, Ben-Neriah S, Woolcock
BW, Mottok A, Tan KL, Slack GW, Gunawardana J, Lim RS, McPherson
AW, et al: Genomic rearrangements involving programmed death
ligands are recurrent in primary mediastinal large B-cell lymphoma.
Blood. 123:2062–2065. 2014.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Prestipino A, Emhardt AJ, Aumann K,
O'Sullivan D, Gorantla SP, Duquesne S, Melchinger W, Braun L,
Vuckovic S, Boerries M, et al: Oncogenic JAK2V617F
causes PD-L1 expression, mediating immune escape in
myeloproliferative neoplasms. Sci Transl Med.
10(eaam7729)2018.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Sato H, Niimi A, Yasuhara T, Permata TBM,
Hagiwara Y, Isono M, Nuryadi E, Sekine R, Oike T, Kakoti S, et al:
DNA double-strand break repair pathway regulates PD-L1 expression
in cancer cells. Nat Commun. 8(1751)2017.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Sun LL, Yang RY, Li CW, Chen MK, Shao B,
Hsu JM, Chan LC, Yang Y, Hsu JL, Lai YJ and Hung MC: Inhibition of
ATR downregulates PD-L1 and sensitizes tumor cells to T
cell-mediated killing. Am J Cancer Res. 8:1307–1316.
2018.PubMed/NCBI
|
|
62
|
Wang Q, Lin W, Tang X, Li S, Guo L, Lin Y
and Kwok HF: The roles of microRNAs in regulating the expression of
PD-1/PD-L1 immune checkpoint. Int J Mol Sci.
18(2540)2017.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Xie G, Li W, Li R, Wu K, Zhao E, Zhang Y,
Zhang P, Shi L, Wang D, Yin Y, et al: Helicobacter pylori promote
B7-H1 expression by suppressing miR-152 and miR-200b in gastric
cancer cells. PLoS One. 12(e0168822)2017.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Xu S, Tao Z, Hai B, Liang H, Shi Y, Wang
T, Song W, Chen Y, OuYang J, Chen J, et al: MiR-424(322) reverses
chemoresistance via T-cell immune response activation by blocking
the PD-L1 immune checkpoint. Nat Commun. 7(11406)2016.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Kataoka K, Shiraishi Y, Takeda Y, Sakata
S, Matsumoto M, Nagano S, Maeda T, Nagata Y, Kitanaka A, Mizuno S,
et al: Aberrant PD-L1 expression through 3'-UTR disruption in
multiple cancers. Nature. 534:402–406. 2016.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Deng S, Hu Q, Zhang H, Yang F, Peng C and
Huang C: HDAC3 inhibition upregulates PD-L1 expression in B-cell
lymphomas and augments the efficacy of anti-PD-L1 therapy. Mol
Cancer Ther. 18:900–908. 2019.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Woods DM, Sodré AL, Villagra A, Sarnaik A,
Sotomayor EM and Weber J: HDAC inhibition upregulates PD-1 ligands
in melanoma and augments immunotherapy with PD-1 blockade. Cancer
Immunol Res. 3:1375–1385. 2015.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Lu C, Paschall AV, Shi H, Savage N, Waller
JL, Sabbatini ME, Oberlies NH, Pearce C and Liu K: The MLL1-H3K4me3
axis-mediated PD-L1 expression and pancreatic cancer immune
evasion. J Natl Cancer Inst. 109(djw283)2017.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Casey SC, Tong L, Li Y, Do R, Walz S,
Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M and Felsher
DW: MYC regulates the antitumor immune response through CD47 and
PD-L1. Science. 352:227–231. 2016.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Marzec M, Zhang Q, Goradia A, Raghunath
PN, Liu X, Paessler M, Wang HY, Wysocka M, Cheng M, Ruggeri BA and
Wasik MA: Oncogenic kinase NPM/ALK induces through STAT3 expression
of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad
Sci USA. 105:20852–20857. 2008.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Akbay EA, Koyama S, Carretero J, Altabef
A, Tchaicha JH, Christensen CL, Mikse OR, Cherniack AD, Beauchamp
EM, Pugh TJ, et al: Activation of the PD-1 pathway contributes to
immune escape in EGFR-driven lung tumors. Cancer Discov.
3:1355–1363. 2013.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Atefi M, Avramis E, Lassen A, Wong DJ,
Robert L, Foulad D, Cerniglia M, Titz B, Chodon T, Graeber TG, et
al: Effects of MAPK and PI3K pathways on PD-L1 expression in
melanoma. Clin Cancer Res. 20:3446–3457. 2014.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Barsoum IB, Smallwood CA, Siemens DR and
Graham CH: A mechanism of hypoxia-mediated escape from adaptive
immunity in cancer cells. Cancer Res. 74:665–674. 2014.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Jiang X, Zhou J, Giobbie-Hurder A, Wargo J
and Hodi FS: The activation of MAPK in melanoma cells resistant to
BRAF inhibition promotes PD-L1 expression that is reversible by MEK
and PI3K inhibition. Clin Cancer Res. 19:598–609. 2013.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Peng J, Hamanishi J, Matsumura N, Abiko K,
Murat K, Baba T, Yamaguchi K, Horikawa N, Hosoe Y, Murphy SK, et
al: Chemotherapy induces programmed cell death-ligand 1
overexpression via the nuclear factor-κB to foster an
immunosuppressive tumor microenvironment in ovarian cancer. Cancer
Res. 75:5034–5045. 2015.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Xu C, Fillmore CM, Koyama S, Wu H, Zhao Y,
Chen Z, Herter-Sprie GS, Akbay EA, Tchaicha JH, Altabef A, et al:
Loss of Lkb1 and pten leads to lung squamous cell carcinoma with
elevated PD-L1 expression. Cancer Cell. 25:590–604. 2014.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Dong H, Strome SE, Salomao DR, Tamura H,
Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K, et al:
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential
mechanism of immune evasion. Nat Med. 8:793–800. 2002.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Garcia-Diaz A, Shin DS, Moreno BH, Saco J,
Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X,
et al: Interferon receptor signaling pathways regulating PD-L1 and
PD-L2 Expression. Cell Rep. 19:1189–1201. 2017.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Carbotti G, Barisione G, Airoldi I,
Mezzanzanica D, Bagnoli M, Ferrero S, Petretto A, Fabbi M and
Ferrini S: IL-27 induces the expression of IDO and PD-L1 in human
cancer cells. Oncotarget. 6:43267–43280. 2015.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Lienlaf M, Perez-Villarroel P, Knox T,
Pabon M, Sahakian E, Powers J, Woan K V, Lee C, Cheng F, Deng S, et
al: Essential role of HDAC6 in the regulation of PD-L1 in melanoma.
Mol Oncol. 10:735–750. 2016.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Ni XY, Sui HX, Liu Y, Ke SZ, Wang YN and
Gao FG: TGF-β of lung cancer microenvironment upregulates B7H1 and
GITRL expression in dendritic cells and is associated with
regulatory T cell generation. Oncol Rep. 28:615–621.
2012.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Pulko V, Liu X, Krco CJ, Harris KJ,
Frigola X, Kwon ED and Dong H: TLR3-stimulated dendritic cells
up-regulate B7-H1 expression and influence the magnitude of CD8 T
cell responses to tumor vaccination. J Immunol. 183:3634–3641.
2009.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Quandt D, Jasinski-Bergner S, Müller U,
Schulze B and Seliger B: Synergistic effects of IL-4 and TNFα on
the induction of B7-H1 in renal cell carcinoma cells inhibiting
allogeneic T cell proliferation. J Transl Med.
12(151)2014.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Wang X, Yang L, Huang F, Zhang Q, Liu S,
Ma L and You Z: Inflammatory cytokines IL-17 and TNF-α up-regulate
PD-L1 expression in human prostate and colon cancer cells. Immunol
Lett. 184:7–14. 2017.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Zhang N, Zeng Y, Du W, Zhu J, Shen D, Liu
Z and Huang JA: The EGFR pathway is involved in the regulation of
PD-L1 expression via the IL-6/JAK/STAT3 signaling pathway in
EGFR-mutated non-small cell lung cancer. Int J Oncol. 49:1360–1368.
2016.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo
CW, Khoo KH, Chang SS, Cha JH, Kim T, et al: Glycosylation and
stabilization of programmed death ligand-1 suppresses T-cell
activity. Nat Commun. 7(12632)2016.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Chan LC, Li CW, Xia W, Hsu JM, Lee HH, Cha
JH, Wang HL, Yang WH, Yen EY, Chang WC, et al: IL-6/JAK1 pathway
drives PD-L1 Y112 phosphorylation to promote cancer immune evasion.
J Clin Invest. 129:3324–3338. 2019.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Mezzadra R, Sun C, Jae LT, Gomez-Eerland
R, de Vries E, Wu W, Logtenberg MEW, Slagter M, Rozeman EA, Hofland
I, et al: Identification of CMTM6 and CMTM4 as PD-L1 protein
regulators. Nature. 549:106–110. 2017.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Yang Y, Hsu JM, Sun L, Chan LC, Li CW, Hsu
JL, Wei Y, Xia W, Hou J, Qiu Y and Hung MC: Palmitoylation
stabilizes PD-L1 to promote breast tumor growth. Cell Res.
29:83–86. 2019.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Schmelzle T and Hall MN: TOR, a central
controller of cell growth. Cell. 103:253–262. 2000.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Lastwika KJ, Wilson W III, Li QK, Norris
J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S, et
al: Control of PD-L1 expression by oncogenic activation of the
AKT-mTOR pathway in non-small cell lung cancer. Cancer Res.
76:227–238. 2016.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Hay N: The Akt-mTOR tango and its
relevance to cancer. Cancer Cell. 8:179–183. 2005.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Aoki M and Fujishita T: Oncogenic roles of
the PI3K/AKT/mTOR Axis. Curr Top Microbiol Immunol. 407:153–189.
2017.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Song M, Chen D, Lu B, Wang C, Zhang J,
Huang L, Wang X, Timmons CL, Hu J, Liu B, et al: PTEN Loss
Increases PD-L1 protein expression and affects the correlation
between PD-L1 expression and clinical parameters in colorectal
cancer. PLoS One. 8(e65821)2013.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Zhang X, Zeng Y, Qu Q, Zhu J, Liu Z, Ning
W, Zeng H, Zhang N, Du W, Chen C and Huang JA: PD-L1 induced by
IFN-γ from tumor-associated macrophages via the JAK/STAT3 and
PI3K/AKT signaling pathways promoted progression of lung cancer.
Int J Clin Oncol. 22:1026–1033. 2017.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Parsa AT, Waldron JS, Panner A, Crane CA,
Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, et
al: Loss of tumor suppressor PTEN function increases B7-H1
expression and immunoresistance in glioma. Nat Med. 13:84–88.
2007.PubMed/NCBI View
Article : Google Scholar
|
|
97
|
Mittendorf EA, Philips AV, Meric-Bernstam
F, Qiao N, Wu Y, Harrington S, Su X, Wang Y, Gonzalez-Angulo AM,
Akcakanat A, et al: PD-L1 expression in triple-negative breast
cancer. Cancer Immunol Res. 2:361–370. 2014.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Akula SM, Abrams SL, Steelman LS, Emma MR,
Augello G, Cusimano A, Azzolina A, Montalto G, Cervello M and
McCubrey JA: RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53
pathways and regulatory miRs as therapeutic targets in
hepatocellular carcinoma. Expert Opin Ther Targets. 23:915–929.
2019.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Wang Z, Ma L, Su M, Zhou Y, Mao K, Li C,
Peng G, Zhou C, Shen B and Dou J: Baicalin induces cellular
senescence in human colon cancer cells via upregulation of DEPP and
the activation of Ras/Raf/MEK/ERK signaling. Cell Death Dis.
9(217)2018.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Wang A, Zhang H, Liang Z, Xu K, Qiu W,
Tian Y, Guo H, Jia J, Xing E, Chen R, et al: U0126 attenuates
ischemia/reperfusion-induced apoptosis and autophagy in myocardium
through MEK/ERK/EGR-1 pathway. Eur J Pharmacol. 788:280–285.
2016.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Wang J, Whiteman MW, Lian H, Wang G, Singh
A, Huang D and Denmark T: A non-canonical MEK/ERK signaling pathway
regulates autophagy via regulating Beclin 1. J Biol Chem.
284:21412–21424. 2009.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Corcelle E, Nebout M, Bekri S, Gauthier N,
Hofman P, Poujeol P, Fénichel P and Mograbi B: Disruption of
autophagy at the maturation step by the carcinogen lindane is
associated with the sustained mitogen-activated protein
kinase/extracellular signal-regulated kinase activity. Cancer Res.
66:6861–6870. 2006.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Liu J, Hamrouni A, Wolowiec D, Coiteux V,
Kuliczkowski K, Hetuin D, Saudemont A and Quesnel B: Plasma cells
from multiple myeloma patients express B7-H1 (PD-L1) and increase
expression after stimulation with IFN-{gamma} and TLR ligands via a
MyD88-, TRAF6-, and MEK-dependent pathway. Blood. 110:296–304.
2007.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Loi S, Dushyanthen S, Beavis PA, Salgado
R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV,
et al: RAS/MAPK activation is associated with reduced
tumor-infiltrating lymphocytes in triple-negative breast cancer:
Therapeutic cooperation between MEK and PD-1/PD-L1 immune
checkpoint inhibitors. Clin Cancer Res. 22:1499–1509.
2016.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Karakhanova S, Meisel S, Ring S, Mahnke K
and Enk AH: ERK/p38 MAP-kinases and PI3K are involved in the
differential regulation of B7-H1 expression in DC subsets. Eur J
Immunol. 40:254–266. 2010.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Qian Y, Deng J, Geng L, Xie H, Jiang G,
Zhou L, Wang Y, Yin S, Feng X, Liu J, et al: TLR4 signaling induces
B7-H1 expression through MAPK pathways in bladder cancer cells.
Cancer Invest. 26:816–821. 2008.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Yamamoto R, Nishikori M, Tashima M, Sakai
T, Ichinohe T, Takaori-Kondo A, Ohmori K and Uchiyama T: B7-H1
expression is regulated by MEK/ERK signaling pathway in anaplastic
large cell lymphoma and Hodgkin lymphoma. Cancer Sci.
100:2093–2100. 2009.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Coelho MA, de Carné Trécesson S, Rana S,
Zecchin D, Moore C, Molina-Arcas M, East P, Spencer-Dene B, Nye E,
Barnouin K, et al: Oncogenic RAS signaling promotes tumor
immunoresistance by stabilizing PD-L1 mRNA. Immunity.
47:1083–1099.e6. 2017.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Gao H, Zhang J and Ren X: PD-L1 regulates
tumorigenesis and autophagy of ovarian cancer by activating mTORC
signaling. Biosci Rep. 39(BSR20191041)2019.PubMed/NCBI View Article : Google Scholar
|
